NewGen Regains Compliance with Nasdaq Minimum Bid Price Requirement and Announces Listing Transfer to the Nasdaq Capital Market
NewGenIvf Group (NIVF) has successfully regained compliance with Nasdaq's minimum bid price requirement, as announced on February 27, 2025. The company had previously received a non-compliance notice on October 8, 2024, when its Class A Ordinary Shares traded below $1.00 for 30 consecutive business days.
The compliance was achieved after the company's shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days from February 11-26, 2025. Additionally, NIVF received approval to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective February 28, 2025. The company's ordinary shares and warrants will continue trading under the symbols 'NIVF' and 'NIVFW' respectively, with no expected impact on securities trading.
NewGenIvf Group (NIVF) ha ripristinato con successo la conformità ai requisiti di prezzo minimo delle azioni di Nasdaq, come annunciato il 27 febbraio 2025. L'azienda aveva precedentemente ricevuto una notifica di non conformità l'8 ottobre 2024, quando le sue azioni ordinarie di Classe A erano scambiate a meno di $1,00 per 30 giorni lavorativi consecutivi.
La conformità è stata raggiunta dopo che le azioni della società hanno mantenuto un prezzo di chiusura di offerta di $1,00 o superiore per 10 giorni lavorativi consecutivi dal 11 al 26 febbraio 2025. Inoltre, NIVF ha ricevuto l'approvazione per trasferire la sua quotazione dal Nasdaq Global Market al Nasdaq Capital Market, a partire dal 28 febbraio 2025. Le azioni ordinarie e i warrant della società continueranno a essere scambiati con i simboli 'NIVF' e 'NIVFW' rispettivamente, senza alcun impatto previsto sul trading dei titoli.
NewGenIvf Group (NIVF) ha recuperado con éxito el cumplimiento del requisito de precio mínimo de oferta de Nasdaq, como se anunció el 27 de febrero de 2025. La compañía había recibido previamente un aviso de incumplimiento el 8 de octubre de 2024, cuando sus acciones ordinarias de Clase A se negociaban por debajo de $1.00 durante 30 días hábiles consecutivos.
El cumplimiento se logró después de que las acciones de la compañía mantuvieron un precio de oferta de cierre de $1.00 o más durante 10 días hábiles consecutivos del 11 al 26 de febrero de 2025. Además, NIVF recibió la aprobación para transferir su cotización del Nasdaq Global Market al Nasdaq Capital Market, con efecto a partir del 28 de febrero de 2025. Las acciones ordinarias y los warrants de la compañía continuarán negociándose bajo los símbolos 'NIVF' y 'NIVFW', respectivamente, sin impacto esperado en el comercio de valores.
NewGenIvf Group (NIVF)는 2025년 2월 27일 발표된 바와 같이 Nasdaq의 최소 매도 가격 요건을 성공적으로 회복했습니다. 이 회사는 2024년 10월 8일에 클래스 A 보통주가 30일 연속으로 $1.00 이하로 거래되었을 때 비준수 통지를 받았습니다.
회사는 2025년 2월 11일부터 26일까지 10일 연속으로 $1.00 이상의 종가를 유지한 후 준수를 달성했습니다. 또한, NIVF는 2025년 2월 28일부터 Nasdaq Global Market에서 Nasdaq Capital Market으로 상장 이전을 승인받았습니다. 회사의 보통주 및 워런트는 각각 'NIVF' 및 'NIVFW' 기호로 계속 거래되며, 증권 거래에 미치는 영향은 예상되지 않습니다.
NewGenIvf Group (NIVF) a réussi à rétablir sa conformité avec l'exigence de prix minimum des actions de Nasdaq, comme annoncé le 27 février 2025. L'entreprise avait précédemment reçu un avis de non-conformité le 8 octobre 2024, lorsque ses actions ordinaires de Classe A étaient échangées en dessous de 1,00 $ pendant 30 jours ouvrables consécutifs.
La conformité a été atteinte après que les actions de l'entreprise ont maintenu un prix d'offre de clôture de 1,00 $ ou plus pendant 10 jours ouvrables consécutifs du 11 au 26 février 2025. De plus, NIVF a reçu l'approbation pour transférer sa cotation du Nasdaq Global Market au Nasdaq Capital Market, à compter du 28 février 2025. Les actions ordinaires et les warrants de l'entreprise continueront d'être échangés sous les symboles 'NIVF' et 'NIVFW' respectivement, sans impact prévu sur le commerce des valeurs mobilières.
NewGenIvf Group (NIVF) hat erfolgreich die Einhaltung der Mindestkursanforderung von Nasdaq wiederhergestellt, wie am 27. Februar 2025 bekannt gegeben wurde. Das Unternehmen hatte zuvor am 8. Oktober 2024 eine Mitteilung über die Nichterfüllung erhalten, als seine Class A-Stammaktien 30 aufeinanderfolgende Handelstage unter $1,00 gehandelt wurden.
Die Einhaltung wurde erreicht, nachdem die Aktien des Unternehmens vom 11. bis 26. Februar 2025 10 Handelstage lang einen Schlusskurs von $1,00 oder höher gehalten hatten. Darüber hinaus erhielt NIVF die Genehmigung, seine Notierung vom Nasdaq Global Market auf den Nasdaq Capital Market zu übertragen, die am 28. Februar 2025 wirksam wird. Die Stammaktien und Warrants des Unternehmens werden weiterhin unter den Symbolen 'NIVF' und 'NIVFW' gehandelt, ohne dass Auswirkungen auf den Wertpapierhandel erwartet werden.
- Regained Nasdaq listing compliance
- Maintained share price above $1.00 for required period
- Secured continued Nasdaq trading status through Capital Market transfer
- Downgrade from Nasdaq Global Market to Capital Market
- Previous trading below $1.00 minimum requirement
BANGKOK, Feb. 28, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments, today announced that it has received a written notice (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) dated February 27, 2025, informing the Company that it has regained compliance with the minimum bid price requirement set forth under the Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).
As previously announced, the Company was notified by Nasdaq on October 8, 2024, that the Company was not in compliance with the Minimum Bid Price Requirement as the closing bid price of the Company’s Class A Ordinary Shares (“Ordinary Shares”) was below
Additionally, the Company has received a written notice (the “Transfer Notice”) from the Listing Qualifications Department of Nasdaq dated February 27, 2025, informing the Company that it has received approval to transfer the listing of its securities from the Nasdaq Global Market to the Nasdaq Capital Market. The Company’s Ordinary Shares and publicly traded warrants will continue to trade under the symbols “NIVF” and “NIVFW,” respectively. The transfer of the Company’s listing to the Nasdaq Capital Market is not expected to have any impact on trading in the Company’s securities. This transfer is expected to take effect as of the opening of trading on February 28, 2025.
About NewGen
NewGen is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. With a mission to aid couples and individuals in building families regardless of fertility challenges, NewGen has dedicated itself to creating increased access to infertility treatment and providing comprehensive fertility services for its customers. NewGen’s management team collectively has over a decade of experience in the fertility industry. NewGen’s clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions, respectively. To learn more, visit www.newgenivf.com. The information contained on, or accessible through, NewGen’s website is not incorporated by reference into this press release, and you should not consider it a part of this press release.
Forward-Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations, business strategy, and financial condition. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release. You should carefully consider the foregoing factors and the other risks and uncertainties described in the Company’s annual report on Form 20-F and other documents filed or to be filed by the Company with the SEC from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com
FAQ
When did NewGenIvf (NIVF) regain Nasdaq compliance?
What caused NIVF's initial Nasdaq non-compliance notice?
What is NIVF's new trading market on Nasdaq?
Will NIVF's stock symbol change after the Nasdaq Capital Market transfer?
